The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Prognostic Significance of CEBPA Mutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of Double CEBPA Mutations and the Interaction With FLT3 and NPM1 Mutations
Abstract
Purpose: To determine the clinical relevance of mutations in the CCAAT/enhancer binding protein α (CEBPA) gene in acute myeloid leukemia (AML) and to examine factors that might modify prognostic impact. Patients and Methods: The entire CEBPA coding sequence was screened in 1,427 young adult patients with AML, excluding acute promyelocytic leukemia, using denaturing high-performance liquid chromatography and direct sequencing. Results: Of 107 patients (7%) with CEBPA mutations, 48 patients (45%) had one mutation (CEBPA-single), and 59 patients (55%) had two mutations (CEBPA-double). The incidence of CEBPA-double patients was similar in intermediate cytogenetic risk patients with and without a normal karyotype (6% and 5%, respectively). CEBPA-double patients had evidence of a lower coincidence with FLT3/ITDs (P = .04) and were highly unlikely to have an NPM1 mutation (P < .0001). CEBPA-double but not CEBPA-single patients had a significantly better overall survival (OS) at 8 years (34%, 31%, and 54% for CEBPA–wild-type [WT], CEBPA-single, and CEBPA-double, respectively, P = .004). This benefit was lost in the presence of a FLT3/ITD (OS for CEBPA-WT, CEBPA-single, and CEBPA-double FLT3/ITD-negative patients: 36%, 35%, 59%, respectively, P = .002; OS for CEBPA-WT, CEBPA-single, and CEBPA-double FLT3/ITD-positive patients: 26%, 21%, 14%, respectively, P = .05). There was no evidence of any additional favorable benefit for a CEBPA-single mutation in the presence of an NPM1 mutation (OS, 45%, 44%, and 56%, P = .2, for NPM1-positive/CEBPA-WT, NPM1-positive/CEBPA-single, and NPM1-negative/CEBPA-double patients, respectively). Conclusion: Screening for CEBPA mutations can be restricted to patients with intermediate-risk cytogenetics lacking an FLT3/ITD or NPM1 mutation. Only the presence of a CEBPA-double mutation should be used for therapy risk stratification.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
Self-citationMutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628
Kottaridis, P. D., Gale, R. E., Frew, M. E., Harrison, G., Langabeer, S. E., Belton, A. A., Walker, H., Wheatley, K., Bowen, D. T., Burnett, A. K., et al. (2001) · Blood · doi:10.1182/blood.v98.6.1752 · Cited by 1,551
Self-citationZhang, D.-E., Zhang, P., Wang, N.-D., Hetherington, C. J., Darlington, G. J., & Tenen, D. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.569 · Cited by 910
Pabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., & Tenen, D. G. (2001) · Nature Genetics · doi:10.1038/85820 · Cited by 901
Gale, R. E., Green, C., Allen, C., Mead, A. J., Burnett, A. K., Hills, R. K., & Linch, D. C. (2008) · Blood · doi:10.1182/blood-2007-08-109090 · Cited by 745
Self-citationTranscription Factors, Normal Myeloid Development, and Leukemia
Tenen, D. G., Hromas, R., Licht, J. D., & Zhang, D.-E. (1997) · Blood · doi:10.1182/blood.v90.2.489 · Cited by 735
Wouters, B. J., Löwenberg, B., Erpelinck-Verschueren, C. A. J., van Putten, W. L. J., Valk, P. J. M., & Delwel, R. (2009) · Blood · doi:10.1182/blood-2008-09-179895 · Cited by 566
Zhang, P., Iwasaki-Arai, J., Iwasaki, H., Fenyus, M. L., Dayaram, T., Owens, B. M., Shigematsu, H., Levantini, E., Huettner, C. S., Lekstrom-Himes, J. A., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.11.006 · Cited by 504
Preudhomme, C., Sagot, C., Boissel, N., Cayuela, J.-M., Tigaud, I., de Botton, S., Thomas, X., Raffoux, E., Lamandin, C., Castaigne, S., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0990 · Cited by 501
Fröhling, S., Schlenk, R. F., Stolze, I., Bihlmayr, J., Benner, A., Kreitmeier, S., Tobis, K., Döhner, H., & Döhner, K. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.060 · Cited by 458
Mutation of CEBPA in Familial Acute Myeloid Leukemia
Smith, M. L., Cavenagh, J. D., Lister, T. A., & Fitzgibbon, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041331 · Cited by 328
Marcucci, G., Maharry, K., Radmacher, M. D., Mrózek, K., Vukosavljevic, T., Paschka, P., Whitman, S. P., Langer, C., Baldus, C. D., Liu, C.-G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5554 · Cited by 302
Hann, I. M., Stevens, R. F., Goldstone, A. H., Rees, J. K. H., Wheatley, K., Gray, R. G., & Burnett, A. K. (1997) · Blood · doi:10.1182/blood.v89.7.2311 · Cited by 297
Self-citationGombart, A. F., Hofmann, W.-K., Kawano, S., Takeuchi, S., Krug, U., Kwok, S. H., Larsen, R. J., Asou, H., Miller, C. W., Hoelzer, D., et al. (2002) · Blood · doi:10.1182/blood.v99.4.1332 · Cited by 293
Kirstetter, P., Schuster, M. B., Bereshchenko, O., Moore, S., Dvinge, H., Kurz, E., Theilgaard-Mönch, K., Månsson, R., Pedersen, T. Å., Pabst, T., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.02.008 · Cited by 251
van Waalwijk van Doorn-Khosrovani, S. B., Erpelinck, C., Meijer, J., van Oosterhoud, S., van Putten, W. L. J., Valk, P. J. M., Berna Beverloo, H., Tenen, D. G., Löwenberg, B., & Delwel, R. (2003) · The Hematology Journal · doi:10.1038/sj.thj.6200216 · Cited by 235
Burnett, A. K., Hills, R. K., Milligan, D. W., Goldstone, A. H., Prentice, A. G., McMullin, M., Duncombe, A. S., Gibson, B. E. S., & Wheatley, K. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.9088 · Cited by 230
Self-citationPabst, T., Eyholzer, M., Haefliger, S., Schardt, J., & Mueller, B. U. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5563 · Cited by 201
Pabst, T., Eyholzer, M., Fos, J., & Mueller, B. U. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604977 · Cited by 163
Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2
Snaddon, J., Smith, M. L., Neat, M. J., Cambal‐Parrales, M., Dixon‐McIver, A., Arch, R., Amess, J. A. L., Rohatiner, A. Z. S., Lister, T. A., & Fitzgibbon, J. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10185 · Cited by 119
Renneville, A., Boissel, N., Gachard, N., Naguib, D., Bastard, C., de Botton, S., Nibourel, O., Pautas, C., Reman, O., Thomas, X., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194704 · Cited by 94
Novel regions of acquired uniparental disomy discovered in acute myeloid leukemia
Gupta, M., Raghavan, M., Gale, R. E., Chelala, C., Allen, C. G., Molloy, G. Y., Chaplin, T., Linch, D. C., Cazier, J., & Young, B. D. (2008) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20573 · Cited by 90
Self-citationFurther evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia
Sellick, G. S., Spendlove, H. E., Catovsky, D., Pritchard‐Jones, K., & Houlston, R. S. (2005) · Leukemia · doi:10.1038/sj.leu.2403788 · Cited by 75
Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia
Benthaus, T., Schneider, F., Mellert, G., Zellmeier, E., Schneider, S., Kakadia, P. M., Hiddemann, W., Bohlander, S. K., Feuring‐Buske, M., Braess, J., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07328.x · Cited by 70
Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation
Renneville, A., Mialou, V., Philippe, N., Kagialis‐Girard, S., Biggio, V., Zabot, M.-T., Thomas, X., Bertrand, Y., & Preudhomme, C. (2008) · Leukemia · doi:10.1038/leu.2008.294 · Cited by 53
Wouters, B. J., Louwers, I., Valk, P. J. M., Löwenberg, B., & Delwel, R. (2007) · Blood · doi:10.1182/blood-2006-08-042325 · Cited by 39
A Comparison of Two Methods for Screening CEBPA Mutations in Patients with Acute Myeloid Leukemia
Ahn, J.-Y., Seo, K., Weinberg, O. K., Boyd, S. D., & Arber, D. A. (2009) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2009.080121 · Cited by 35
Nanri, T., Uike, N., Kawakita, T., Iwanaga, E., Hoshino, K., Mitsuya, H., & Asou, N. (2006) · Blood · doi:10.1182/blood.v108.11.1916.1916 · Cited by 13
Juhl‐Christensen, C., Bomberg, M., Melsvik, D., Hokland, P., & Nyvold, C. G. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01117.x · Cited by 9
Corbacioglu, A., Fröhling, S., Mendla, C., et al. (2007) · Blood · doi:10.1182/blood.v110.11.363.363 · Cited by 6
Cited by
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Burnett, A. K., Hills, R. K., Milligan, D., Kjeldsen, L., Kell, J., Russell, N. H., Yin, J. A. L., Hunter, A., Goldstone, A. H., & Wheatley, K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.4310 · Cited by 657
Self-citationMolecular landscape of acute myeloid leukemia in younger adults and its clinical relevance
Grimwade, D., Ivey, A., & Huntly, B. J. P. (2016) · Blood · doi:10.1182/blood-2015-07-604496 · Cited by 445
Cornelissen, J. J., Gratwohl, A., Schlenk, R. F., Sierra, J., Bornhäuser, M., Juliusson, G., Råcil, Z., Rowe, J. M., Russell, N., Mohty, M., et al. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.150 · Cited by 400
Metadata
- Authors
- Green, C. L., Koo, K. K., Hills, R. K., Burnett, A. K., Linch, D. C., & Gale, R. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-06-01
- Volume
- 28
- Issue
- 16
- Pages
- 2739-2747
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2098272196
- Cited by
- 273
- References
- 31
- FWCI
- 15.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.